SI-BONE Beheer
Beheer criteriumcontroles 2/4
De CEO SI-BONE is Laura Francis, benoemd in Apr2021, heeft een ambtstermijn van 5.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 7.45M, bestaande uit 9.2% salaris en 90.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.09% van de aandelen van het bedrijf, ter waarde $ 7.06M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.1 jaar en 15.4 jaar.
Belangrijke informatie
Laura Francis
Algemeen directeur
US$7.5m
Totale compensatie
| Percentage CEO-salaris | 9.19% |
| Dienstverband CEO | 5.1yrs |
| Eigendom CEO | 1.1% |
| Management gemiddelde ambtstermijn | 5.1yrs |
| Gemiddelde ambtstermijn bestuur | 15.4yrs |
Recente managementupdates
Recent updates
Narratiefupdate • May 22
SIBN: 2026 Guidance And Trauma Partnership Will Drive Further Upside
Analysts have trimmed their price target on SI-BONE from $22.00 to $18.00 as updated assumptions now reflect slightly lower revenue growth, a modestly reduced profit margin outlook, and a lower future P/E multiple, partly offset by a small adjustment to the discount rate. What's in the News SI-BONE issued earnings guidance for 2026, with worldwide revenue expected in a range of $228.5 million to $232.5 million, implying year-over-year growth of about 14% to 16% (Key Developments).Analyseartikel • May 14
Analysts Have Been Trimming Their SI-BONE, Inc. (NASDAQ:SIBN) Price Target After Its Latest Report
SI-BONE, Inc. ( NASDAQ:SIBN ) just released its latest first-quarter results and things are looking bullish. Results...Narratiefupdate • Apr 12
SIBN: 2026 Guidance And Trauma Partnership Will Support Further Upside
Analysts have kept SI-BONE's price target steady at $22.00, citing only modest tweaks to inputs such as the discount rate, revenue growth, profit margin, and forward P/E assumptions, rather than any major change in their overall view. What's in the News Smith+Nephew signed a distribution agreement with SI-BONE focused on the iFuse TORQ portfolio for percutaneous pelvic fracture fixation procedures and sacroiliac joint fusion, expanding access to these products through Smith+Nephew's trauma portfolio and SI-BONE's existing sales channel (Key Developments).Narratiefupdate • Mar 29
SIBN: 2026 Outlook And Pelvic Fixation Partnership Will Support Upside
Analysts now hold their price target for SI-BONE steady at $22.00. This reflects only small tweaks to assumptions around discount rate, revenue growth, profit margin, and future P/E that do not materially shift their overall valuation view.Narratiefupdate • Mar 11
SIBN: 2026 Revenue Outlook And Pelvic Fixation Deal Will Support Upside
Analysts have held their SI-BONE price target steady at $22.00, with only modest tweaks to assumptions on discount rate, revenue growth, profit margin, and future P/E, reflecting fine tuning rather than a shift in their overall view. What's in the News Smith+Nephew signed a distribution agreement with SI-BONE focused on the iFuse TORQ portfolio for percutaneous pelvic fracture fixation procedures and sacroiliac (SI) joint fusion, broadening access to these products through Smith+Nephew's trauma channel alongside SI-BONE's existing salesforce (Key Developments).Narratiefupdate • Feb 25
SIBN: 2026 Revenue Outlook And New Distribution Deal Will Support Upside
Analysts have trimmed their price target for SI-BONE from $23.00 to $22.00, reflecting updated assumptions that include slightly lower revenue growth expectations, a modestly higher profit margin outlook, and a revised forward P/E multiple. What's in the News SI-BONE issued earnings guidance for 2026, projecting worldwide revenue in a range of $228.5 million to $232.5 million, with implied year over year growth guidance of about 14% to 16% (company guidance).Narratiefupdate • Jan 19
SIBN: Higher 2025 Revenue Guidance Will Support Future Upside Potential
Analysts have maintained their fair value estimate for SI-BONE at $23.00. They made small adjustments to assumptions such as discount rate, revenue growth, profit margin, and future P/E, which together support this reaffirmed target.Narratiefupdate • Jan 04
SIBN: Raised 2025 Revenue Guidance Will Drive Stronger Profitability And Share Price Upside
Analysts have modestly lowered their price target on SI-BONE to 23.00 dollars per share, reflecting a slightly higher discount rate and a marginally lower expected future price to earnings multiple, even as they factor in stronger long term revenue growth prospects. What's in the News SI-BONE raised its 2025 revenue guidance to a range of 198 million to 200 million dollars, up from 195 million to 198 million dollars previously.Narratiefupdate • Dec 19
SIBN: Raised Revenue Guidance Will Support Stronger Profitability And Share Price Upside
Analysts have raised their price target on SI-BONE from 20 dollars to 23 dollars, citing slightly stronger expectations for revenue growth, profitability, and long term valuation multiples. What's in the News Company raised 2025 revenue guidance to a range of 198 million dollars to 200 million dollars, up from a prior range of 195 million dollars to 198 million dollars, signaling increased confidence in demand trends (company guidance filing) The updated outlook implies faster top line growth than previously anticipated and supports analysts' upward revisions to price targets and long term valuation assumptions (company guidance filing) The narrowing of the revenue guidance range suggests greater visibility into procedure volumes and commercial execution for the remainder of the year (company guidance filing) Valuation Changes The fair value estimate has risen slightly from 20 dollars to 23 dollars per share, reflecting modestly stronger growth and profitability assumptions.Analyseartikel • Nov 13
Earnings Update: SI-BONE, Inc. (NASDAQ:SIBN) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
SI-BONE, Inc. ( NASDAQ:SIBN ) just released its third-quarter report and things are looking bullish. Revenues and...Analyseartikel • Nov 12
Getting In Cheap On SI-BONE, Inc. (NASDAQ:SIBN) Might Be Difficult
SI-BONE, Inc.'s ( NASDAQ:SIBN ) price-to-sales (or "P/S") ratio of 4.1x may not look like an appealing investment...Analyseartikel • Jun 26
Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • May 09
Earnings Update: SI-BONE, Inc. (NASDAQ:SIBN) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
SI-BONE, Inc. ( NASDAQ:SIBN ) investors will be delighted, with the company turning in some strong numbers with its...Analyseartikel • May 08
Revenues Tell The Story For SI-BONE, Inc. (NASDAQ:SIBN) As Its Stock Soars 30%
SI-BONE, Inc. ( NASDAQ:SIBN ) shareholders would be excited to see that the share price has had a great month, posting...Analyseartikel • Mar 27
SI-BONE (NASDAQ:SIBN) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Nieuw narratief • Mar 26
TORQ And TNT Will Expand Market Reach In 2025
Strong product launches and a robust innovation pipeline suggest promising future revenue growth and strengthened market positioning.Analyseartikel • Jan 19
SI-BONE, Inc. (NASDAQ:SIBN) Looks Just Right With A 26% Price Jump
SI-BONE, Inc. ( NASDAQ:SIBN ) shareholders have had their patience rewarded with a 26% share price jump in the last...Analyseartikel • Nov 04
Market Cool On SI-BONE, Inc.'s (NASDAQ:SIBN) Revenues
There wouldn't be many who think SI-BONE, Inc.'s ( NASDAQ:SIBN ) price-to-sales (or "P/S") ratio of 3.7x is worth a...Analyseartikel • Sep 25
Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Analyseartikel • Apr 01
SI-BONE, Inc.'s (NASDAQ:SIBN) P/S Is On The Mark
SI-BONE, Inc.'s ( NASDAQ:SIBN ) price-to-sales (or "P/S") ratio of 4.8x might make it look like a sell right now...Analyseartikel • Feb 29
Analyst Estimates: Here's What Brokers Think Of SI-BONE, Inc. (NASDAQ:SIBN) After Its Full-Year Report
It's been a sad week for SI-BONE, Inc. ( NASDAQ:SIBN ), who've watched their investment drop 14% to US$17.35 in the...Analyseartikel • Feb 28
Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyseartikel • Nov 12
Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyseartikel • Aug 09
Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Apr 20
Is SI-BONE (NASDAQ:SIBN) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyseartikel • Jan 01
Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$17m |
| Dec 31 2025 | US$7m | US$685k | -US$19m |
| Sep 30 2025 | n/a | n/a | -US$22m |
| Jun 30 2025 | n/a | n/a | -US$24m |
| Mar 31 2025 | n/a | n/a | -US$27m |
| Dec 31 2024 | US$7m | US$652k | -US$31m |
| Sep 30 2024 | n/a | n/a | -US$37m |
| Jun 30 2024 | n/a | n/a | -US$41m |
| Mar 31 2024 | n/a | n/a | -US$43m |
| Dec 31 2023 | US$4m | US$622k | -US$43m |
| Sep 30 2023 | n/a | n/a | -US$44m |
| Jun 30 2023 | n/a | n/a | -US$48m |
| Mar 31 2023 | n/a | n/a | -US$55m |
| Dec 31 2022 | US$5m | US$604k | -US$61m |
| Sep 30 2022 | n/a | n/a | -US$65m |
| Jun 30 2022 | n/a | n/a | -US$66m |
| Mar 31 2022 | n/a | n/a | -US$62m |
| Dec 31 2021 | US$3m | US$527k | -US$57m |
| Sep 30 2021 | n/a | n/a | -US$51m |
| Jun 30 2021 | n/a | n/a | -US$45m |
| Mar 31 2021 | n/a | n/a | -US$43m |
| Dec 31 2020 | US$2m | US$386k | -US$44m |
| Sep 30 2020 | n/a | n/a | -US$44m |
| Jun 30 2020 | n/a | n/a | -US$46m |
| Mar 31 2020 | n/a | n/a | -US$42m |
| Dec 31 2019 | US$2m | US$375k | -US$38m |
Compensatie versus markt: De totale vergoeding ($USD 7.45M ) Laura } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 3.70M ).
Compensatie versus inkomsten: De vergoeding van Laura is gestegen terwijl het bedrijf verliesgevend is.
CEO
Laura Francis (58 yo)
5.1yrs
Tenure
US$7,453,235
Compensatie
Ms. Laura A. Francis, MBA, has been an Independent Director of Bruker Corporation since February 18, 2025. She serves as Director at Galvanize Therapeutics, Inc. from November 2025. She serves as Chief Exe...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Executive Chairman | 18.1yrs | US$255.35k | 0.20% $ 1.3m | |
| CEO & Director | 5.1yrs | US$7.45m | 1.09% $ 7.1m | |
| COO & CFO | 5.1yrs | US$2.79m | 0.16% $ 1.0m | |
| Chief Business & Legal Affairs Officer | 9.8yrs | US$2.36m | 0.30% $ 1.9m | |
| Advisor | 9.8yrs | US$2.45m | 0.36% $ 2.3m | |
| Senior VP of Engineering & CTO | no data | geen gegevens | geen gegevens | |
| Vice President of Financial Planning & Analysis and Investor Relations | no data | geen gegevens | geen gegevens | |
| Vice President of Product & Marketing | less than a year | geen gegevens | geen gegevens | |
| Senior Vice President of Clinical | 4.9yrs | geen gegevens | geen gegevens | |
| Chief Medical Officer & VP of Medical Affairs | no data | geen gegevens | geen gegevens | |
| Chief Commercial Officer | 5.1yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Market Access & Reimbursement | less than a year | geen gegevens | geen gegevens |
5.1yrs
Gemiddelde duur
58yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van SIBN is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.1 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Executive Chairman | 18.1yrs | US$255.35k | 0.20% $ 1.3m | |
| CEO & Director | 5.1yrs | US$7.45m | 1.09% $ 7.1m | |
| Lead Independent Director | 18.1yrs | US$240.35k | 0.12% $ 766.7k | |
| Independent Director | 15.3yrs | US$217.60k | 0.39% $ 2.5m | |
| Independent Director | 6.4yrs | US$235.35k | 0.054% $ 354.1k | |
| Independent Director | 13.3yrs | US$215.35k | 0.28% $ 1.9m | |
| Member of Medical Advisory Board | 16.3yrs | geen gegevens | geen gegevens | |
| Member of Medical Advisory Board | 16.3yrs | geen gegevens | geen gegevens | |
| Member of Medical Advisory Board | 16.3yrs | geen gegevens | geen gegevens | |
| Member of Medical Advisory Board | 15.4yrs | geen gegevens | geen gegevens | |
| Independent Director | 5.2yrs | US$220.35k | 0.054% $ 352.7k | |
| Member of Surgeon Advisory Board | no data | geen gegevens | geen gegevens |
15.4yrs
Gemiddelde duur
68yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van SIBN zijn ervaren en ervaren (gemiddelde ambtstermijn van 15.4 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/27 11:26 |
| Aandelenkoers aan het einde van de dag | 2026/05/27 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
SI-BONE, Inc. wordt gevolgd door 16 analisten. 8 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Travis Steed | BofA Global Research |
| Caitlin Cronin | Canaccord Genuity |
| Ross Osborn | Cantor Fitzgerald & Co. |